Last reviewed · How we verify
SENL103
At a glance
| Generic name | SENL103 |
|---|---|
| Sponsor | Hebei Senlang Biotechnology Inc., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. (PHASE1, PHASE2)
- The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis (PHASE1)
- the Safety and Efficacy of SENL103 Autologous T Cell Injection (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SENL103 CI brief — competitive landscape report
- SENL103 updates RSS · CI watch RSS
- Hebei Senlang Biotechnology Inc., Ltd. portfolio CI